Jack Wyszomierski Sells 3,925 Shares of Exelixis (NASDAQ:EXEL) Stock

Posted by Francis Steltz on Jun 5th, 2026

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director Jack Wyszomierski sold 3,925 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $50.55, for a total transaction of $198,408.75. Following the sale, the director directly owned 284,384 shares of the company’s stock, valued at approximately $14,375,611.20. This trade represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Exelixis Price Performance

Shares of EXEL opened at $52.49 on Friday. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $52.96. The company has a 50 day simple moving average of $46.76 and a two-hundred day simple moving average of $44.47. The firm has a market cap of $13.19 billion, a P/E ratio of 17.44, a price-to-earnings-growth ratio of 1.08 and a beta of 0.41.

Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The company’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the firm posted $0.55 EPS. On average, sell-side analysts anticipate that Exelixis, Inc. will post 3.18 earnings per share for the current year.

Analyst Ratings Changes

EXEL has been the subject of a number of research reports. TD Cowen increased their target price on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Stifel Nicolaus increased their target price on Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Truist Financial upgraded Exelixis to a “strong-buy” rating in a research report on Monday, April 27th. Finally, Morgan Stanley increased their target price on Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Exelixis has a consensus rating of “Hold” and a consensus target price of $47.35.

Read Our Latest Stock Report on Exelixis

Institutional Trading of Exelixis

A number of institutional investors have recently bought and sold shares of the stock. Farallon Capital Management LLC lifted its position in Exelixis by 21.6% in the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock worth $805,412,000 after buying an additional 3,466,000 shares during the last quarter. AQR Capital Management LLC lifted its position in Exelixis by 48.8% in the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after buying an additional 4,477,029 shares during the last quarter. Invesco Ltd. lifted its position in Exelixis by 1.6% in the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock worth $265,379,000 after buying an additional 94,218 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Exelixis by 0.9% in the first quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock worth $184,391,000 after buying an additional 39,920 shares during the last quarter. Finally, Morgan Stanley lifted its position in Exelixis by 31.0% in the fourth quarter. Morgan Stanley now owns 4,206,656 shares of the biotechnology company’s stock worth $184,378,000 after buying an additional 995,949 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Exelixis Company Profile

(Get Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.